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Abstract
The phenomenon of antibiotic resistance has created a need for the development of novel
antibiotic classes with non-classical cellular targets. Unfortunately, target-based drug discovery
against proteins considered essential for in vitro bacterial viability has yielded few new therapeutic
classes of antibiotics. Targeting the large proportion of genes considered nonessential that have yet
to be explored by HTS, e.g., RecA, can complement these efforts. Recent evidence suggests that
RecA-controlled processes are responsible for tolerance to antibiotic chemotherapy and are
involved in pathways that ultimately lead to full-fledged antibiotic resistance. Therefore inhibitors
of RecA may serve as therapeutic adjuvants in combination chemotherapy of bacterial infectious
diseases. Towards the goal of validating RecA as a novel target in the chemotherapy of bacterial
infections, we have screened 35,780 small molecules against RecA. In total, 80 small molecules
were identified as primary hits and could be clustered in six distinct chemotype clades. The most
potent class of hits was further examined, and one member compound was found to inhibit RecA-
mediated strand exchange and prevent ciprofloxacin-induced SOS expression in Escherichia coli.
This compound represents the first small molecule demonstrating an ability to inhibit the bacterial
SOS response in live bacterial cell cultures.
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INTRODUCTION
Antibiotic resistance is an escalating problem in the chemotherapy of bacterial infectious
diseases1,2 that erodes the efficacy of current frontline therapeutic agents as well as
undermining the profitability of developing new antibacterial agents.3 As a result, many
pharmaceutical companies have curtailed their antibacterial drug discovery efforts,4 and
since 1962 only three new classes of antibacterial agents have been introduced.5 Novel
strategies will be required to overcome this looming crisis, and one potential solution to the
problem involves screening targets considered non-essential for in vitro viability. Indeed,
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two-thirds of Escherichia coli genes have been characterized as non-essential,6 and
exploring this previously ignored segment of the bacterial genome may offer possibilities for
the discovery of non-traditional pharmaceutical targets and agents that attenuate
pathogenicity or potentiate the pharmacologic effects of known antibacterial agents.7 In this
context, we have focused on the bacterial RecA protein as a prospective target in the
treatment of bacterial infectious diseases. RecA plays crucial roles in the repair of DNA
damage and stalled replication, but also participates in processes that promote stress-induced
mutation and horizontal gene transfer. We hypothesize that small molecule inhibitors of
RecA may sensitize bacteria to established antibacterial agents and prevent the development
and acquisition of genes conferring drug resistance.
E. coli RecA has been identified as a critical component of the response to antibacterial
quinolones that interfere with topoisomerase II, leading to double-stranded DNA breaks and
stalled replication forks, both of which are processed to ssDNA.8 In the event of such DNA
damage, multiple ATP-bound RecA monomers coat the resulting ssDNA, forming a helical
homopolymeric filament of RecA on DNA that has both enzymatic and signaling properties.
This RecA-DNA filament (RDF) mediates recombinational DNA repair, an enzymatic
function that exchanges strands between homologous DNA substrates, and activates
autocleavage of the LexA repressor, a signaling activity that initiates the expression of SOS
genes. The early SOS gene products, including RecA itself, help maintain genetic
homeostasis by high-fidelity repair of the DNA damage, while the late SOS gene products
introduce genome-wide mutations.
E. coli RecA's seemingly antagonistic activities are the basis for both short and long-term
survival responses to antibiotic treatment. RecA-dependent DNA repair apparently leads to
inherent ciprofloxacin tolerance, and ΔrecA strains are more susceptible to cell killing by
ciprofloxacin.9 In addition, RecA-activated SOS mutagenesis results in genetic
diversification that can lead to resistance-conferring mutations, and SOS-deficient strains
adapt much more slowly to ciprofloxacin.10 RecA is a highly conserved bacterial protein
and likely plays similar roles in other species,11 making it an attractive target for the
development of new pharmaceutic adjuvants.12 Unfortunately, no cell-permeable natural
product or synthetic small molecule inhibitors of RecA have been reported to date.
To advance our goal of obtaining cell-permeable small molecules that modulate RecA's
biological activities in live bacterial cell cultures, we have screened a diverse collection of
35,780 drug-like small molecules for the inhibition of RecA. Because all of RecA's
biological activities are expressed from an activated conformation that requires the binding
ATP that is subsequently hydrolyzed,13 the compounds were screened using a colorimetric
ATPase assay adapted for use with RecA. In all, we identified five distinct chemotype
clades capable of abrogating the ATPase activity of RecA in vitro. One such class of
molecules was found to significantly reduce the RecA-dependent activation of the SOS
response in liquid cultures of E. coli resulting from exposure to ciprofloxacin.
MATERIALS AND METHODS
Materials
RecA was purified and stored as previously described.14 Poly(dT) single-stranded DNA
(average length = 319 nucleotides) was purchased from Amersham Biosciences (Piscataway,
NJ). Crystalline L-ascorbic acid and sulfuric acid were purchased from Fisher Scientific.
ϕχ174 circular single-stranded DNA (cssDNA) and double stranded DNA (dsDNA) were
purchased from New England Biolabs (Ipswich, MA). Unless otherwise stated all other
reagents were purchased from Sigma-Aldrich (St. Louis, MO) at the highest level of purity
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possible. E. coli K-12 containing the sulA-gfp reporter gene fusion (SS996 strain)15 was
generously provided by Dr. Steven Sandler at the University of Massachusetts at Amherst.
Compound libraries
The Challenge, Diversity and Natural Product libraries were obtained from the National
Cancer Institute (NCI), Drug Synthesis and Chemistry Branch (Bethesda, MD) as 10 mM
stocks in DMSO. The compounds were diluted to 1 mM stocks in sterile 96-well U-bottom
microplates (Evergreen Scientific, Los Angeles, CA) in DMSO using a TOMTEC 96-
channel pipet tower (TOMTEC, Hamden, CT).
The BRITE compound collection, consisting of a library of over 350,000 compounds
generated by combinatorial chemistry synthetic routes, was a gift from Biogen Idec in 2006.
Upon acquisition, compounds were placed into 100% DMSO at an initial concentration of
10 mM. All of the compound plates were stored in polypropylene deep-well blocks at 4 °C
without humidity controls. Using a Biomek NX unit (Beckman-Coulter, Fullerton, CA), 0.5
μL of a 1 mM stock of library compounds in DMSO was pre-spotted onto Costar clear flat-
bottom 384-well assay plates (Corning, Lowell, MA). In the left and right two columns of
the assay plates 0.5 μL DMSO was spotted for the respective negative and positive control
reactions.
Phosphomolybdate blue ATPase assay
The phosphomolybdate blue dye was made as a 10X stock by adding 30 g ammonium
molybdate to 87 mL concentrated sulfuric acid and adjusting the final volume to 250 mL
with autoclaved MilliQ de-ionized water. On the day of use, fresh 1X phosphomolybdate
blue dye was made by diluting the 10X stock in autoclaved MilliQ de-ionized water and
ascorbic acid and SDS were added to final concentrations of 10% w/v and 1% w/v
respectively.
The ATPase reactions were carried out in the 384-well plates that the compounds were
spotted in, and the final volume in each well was 30.5 μL, giving final concentrations of 17
μM for the library compounds and 1.6 % for DMSO. A 2.25 mM stock of ATP was prepared
in H2O and 10 μL of this was added to all wells of the assay plates using a Thermo
Multidrop dispenser (Thermo Fisher Scientific, Waltham, MA), yielding a final ATP
concentration of 0.75 mM. To columns 3–24 of the assay plates, using a Thermo Multidrop
dispenser, was added 20 μL of a cocktail of containing RecA, poly(dT) ssDNA, MgOAc2
and Tris·Glycerol buffer (pH = 7.5) such that the final concentrations were 0.5 μM RecA, 5
μM-nts poly(dT), 10 mM MgOAc2, 25 mM Tris·HOAc and 5% v/v glycerol. For the
negative control reactions, 20 μL of an identical solution containing no poly(dT) was added
to columns 1 and 2 using a Thermo Multidrop dispenser. To ensure the uniformity of results,
the assay plates were processed in batches of 10. Three Multidrop dispenser stations
containing either ATP, the reaction cocktail or the negative control cocktail were placed in
close proximity. The assay plates were serially moved between the Multidrop stations, each
plate requiring 30 s to fill completely. An entire batch of 10 plates was processed in 5 min,
and upon addition of all reagents the plates were transferred to a 37 °C air incubator and the
ATPase reaction was allowed to proceed for 35 min. Subsequently, the plates were removed
from the incubator and the reactions were stopped by the addition of 30 μL of the 1×
phosphomolybdate blue dye reagent to all wells of the batch of 10 plates in the same order
the reaction cocktail was added. The A650 signals of the stopped reactions were stable for at
least 30 min, and all 10 assay plates could be easily measured in this window. Subsequent
batches of 10 plates were staggered by 15 to 20 min, allowing the operator sufficient time to
manage the manipulation of two batches of 10 plates simultaneously.
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Typically, the plates were scanned for absorbance at 650 nm after standing 5 min at room
temperature using a Spectramax Plus384 microplate reader (Molecular Devices, Sunnyvale,
CA). Screening data informatics were processed using ActivityBase, XLfit (ID Business
Solutions, Bridgewater, NJ) and Microsoft Excel 2003 (Microsoft, Redmond, WA). The
percent-inhibition of RecA ATPase activity was analyzed on a plate-to-plate basis by
comparing the A650 value per compound well with the plate-averaged control wells using
the following relationship:
Eq. (1)
where A650 is the well-specific absorbance value, μmin is the plate-averaged minimum signal
control value, and μmax is the plate-averaged maximum signal control value. No plate
corrections were needed between run-sets.




where σmax and σmin are defined as the calculated standard deviations in the plate positive
and negative controls, σCMPD is the standard deviation in the compound data, σPC is the
standard deviation in the 100% inhibition control, μCMPD and μPC are the respective average
values for the compound data and the 100% inhibition control.
Small molecule inhibition of RecA-mediated three-strand exchange reaction
The ϕχ174 RFI dsDNA was linearized to the RFIII form using XhoI endonuclease (New
England Biolabs, Ipswich, MA) and subsequently gel-purified. Single-stranded DNA
binding protein (SSB) was purchased from Promega (Madison, WI). Strand exchange
promoted by RecA was monitored essentially as previously described.17 Briefly, 10 μM
RecA was incubated at 37 °C for 10 min with 20 μM-nts ϕχ174 cssDNA in 1× Reaction
Buffer (25 mM Tris·HOAc, 5% glycerol, pH = 7.5) with 10 mM Mg(OAc)2, 12 mM
phosphocreatine, 10 U/mL creatine phosphokinase and in the presence or absence of 25 μM
A1. After the initial incubation, 20 μM-nts ϕ χ174 linear dsDNA form III was added and the
mixture was incubated for another 10 min at 37 °C. During this second incubation, 10 μL
was removed as the 0 min aliquot and added to 3.3 μL stop dye (60 mM EDTA, 5% (w/v)
SDS, 25% (w/v) glycerol, 0.2% bromophenol blue) to inactivate RecA and stop the strand
exchange reaction. To initiate the strand exchange reaction 3 mM ATP and 2 μM SSB were
added then placed in a Thermomixer R microplate shaker/incubator (Thermo Fisher
Scientific, Waltham, MA) incubated at 37 °C. Aliquots (10 μL) were taken at 10, 30, 60 and
90 min and added to 3.3 μL of stop dye after the addition of ATP. All of the aliquots were
run on a 0.8% agarose gel for 12 h at 30 V, then stained for 1.5 h with Sybr Gold
(Invitrogen, Carlsbad, CA) for visualization.
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Small molecule inhibition of RecA-dependent SOS activation
We assessed the ability of compound A1 to impact the RecA-dependent induction of the
SOS response using E. coli K-12 having the sulA SOS promoter fused to the green
fluorescent protein (gfp) reporter gene inserted at attλ on the chromosome (strain SS996).15
Fresh 2 mL LB cultures were inoculated with saturated overnight cultures of E. coli SS996
to OD600 = 0.3 in the presence and absence of 100 ng/μL ciprofloxacin and 100 μM A1. The
highest final concentration of DMSO attained from the addition of these compounds was
0.15% and considered negligible. The cultures were grown in a shaking incubator at 37 °C
for 90 min. At the end of this incubation, the cells were stained for 5 min at 25 °C directly in
the LB medium with the addition of 3.7% formaldehyde and 10 μg/mL 4',6-diamidino-2-
phenylindole (DAPI). Following staining, 1.6 mL of cells was centrifuged at 13,000 rpm
(RPM) for 1 min and the supernatant was removed. The cells were washed three times with
10 mM MgSO4 (1 mL) to remove excess DAPI and finally resuspended in 10 mM MgSO4
(500 μL) for imaging.
The cells were diluted (1:10) in clear, flat-bottom 384-well imaging microplates (Greiner,
Monroe, NC) in a volume of 50 μL, sealed and centrifuged for 15 min at 3000 rpm and
imaged in a BD pathway 855 high-content epifluorescence confocal microscope, equipped
with an Olympus 40X/0.90NA objective and a Hamamatsu Orca CCD camera. Multiplexed
two-color images were acquired using the following filters; GFP: 488 nm/10 nm bandwidth
excitation filter, FURA/FITC epifluorescence dichroic and 515 LP emission filter; DAPI:
380 nm/10 nm bandwidth excitation filter, 400 dclp dichroic and 435 nm long-pass emission
filter. Bacterial cell binary masks were generated using the Attovision software (BD
Biosciences, San Jose, CA) to delineate the cell boundaries using the DAPI channel. A
normalized GFP intensity was calculated by integrating the GFP signal divided by the
integrated DAPI intensity within the cell boundary. The average normalized GFP response
per bacterium for a particular well was calculated and compared to other wells.
RESULTS
Assay optimization and validation
RecA is activated in the presence of ssDNA and ATP, forming the RDF that hydrolyzes
ATP. Therefore, ATP hydrolysis serves as a useful indicator of RecA activation, and we
chose to monitor the reduction of ATPase activity as a diagnostic for small-molecule
mediated inhibition of RecA by in vitro screening. Although we successfully used a
validated enzyme-linked fluorogenic ATPase assay18 to screen 2180 compounds from the
National Cancer Institute against RecA (data not shown), we considered more cost-effective
alternative assays. We have experience with several suitable assay technologies,18–20
including the well-known Malachite Green assay,19 but we elected adapt a
phosphomolybdate blue (PMB) colorimetric phosphate detection assay21,22 to identify
compounds that abrogated ATP hydrolysis by RecA. While the fluorogenic assay results can
be observed in real-time, the PMB assay can be performed for roughly 2% of the cost per
well and, in our hands, provides more reliable reaction endpoint data than the Malachite
Green assay (Z' 0.73 vs. 0.68; see below).
The PMB ATPase assay relies on the reaction of a molybdate-ascorbic acid complex with
inorganic phosphate (Pi) to produce an aggregate phosphomolybdate complex having a
strong absorbance in the 600 to 700 nm range. The A650 signal of the PMB phosphate
detection assay remained linear to at least 1.25 mM Pi (Figure 1). Optimization of the assay
protocol was undertaken to maximize the signal-to-noise ratio, which represents a challenge
when using RecA because the equilibrium constant for its self-association during filament
assembly and activation is modest. Thus, in spite of a relatively low turnover number for
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ATP hydrolysis (kcat ≤ 0.5 s−1), the absolute rate of ATP hydrolysis is high under conditions
where RecA-DNA filament formation is favorable.
Guided by our experience with the ssDNA-dependent ATP hydrolysis reaction catalyzed by
RecA,18,19 optimal conditions producing A650 signals in the assay's linear range in 384-well
plates were identified when RecA, poly(dT) and ATP were present at 0.5 μM, 5 μM-nts and
0.75 mM, respectively (data not shown). Importantly, to keep the free phosphate
concentration in the linear dynamic range of the assay reagent, the time of the reactions had
to be limited to no more than 40 min; however, we elected to use 35 min as the longest
allowable reaction time comfortably within the assay's linear dynamic range. Using the PMB
assay, single time-points were taken in a 384-well plate by the addition of the PMB reagent
solution to stop the ATPase reaction, and free phosphate was measured by comparison to a
phosphate standard curve. Absorbance-versus-time plots were constructed for the hydrolysis
reaction in the presence of various initial ATP concentrations and the data were analyzed as
previously described to ensure that established kinetic parameters for steady-state ATP
hydrolysis by RecA were reproduced.19 The RecA concentration (0.5 μM) was the minimal
value necessary to achieve reproducible steady-state ATPase activity and the poly(dT)
concentration (5 μM-nts) was just above that necessary to saturate the RecA under these
reaction conditions.18,19 Above an initial ATP concentration of 0.75 mM, the A650 signal
corresponding to generation of free phosphate increased non-linearly with increasing Pi
concentration (Figure 1), due to the build-up of ADP, a natural feedback inhibitor of RecA-
catalyzed ATP hydrolysis. Under these optimized conditions at 37 °C, neither the extent or
kinetics of the reaction demonstrated sensitivity to the presence of DMSO, up to 10% (v/v).
To evaluate the PMB ATPase assay for robust and reproducible behavior in a 384-well
format, we compared the signal-to-background and signal-to-noise ratios as well as the Z'
factors16 calculated across a 384-well microplate. Over a span of five days, three replicate
assays were performed under the optimized conditions described above to test for interday,
interplate and intercolumn variability. The A650 signal at 35 min was taken as the positive
control value, the value at 35 min when poly(dT) was omitted from the reaction was taken as
the negative control, and the mean positive control and background signals, as well as the
coefficients of variation in each, were compiled for each of three assays (Figure 2). The
overall quality of the PMB RecA HTS ATPase assay was assessed using the Z′ factor, which
defines the difference between the positive and negative controls of the dynamic signal
being measured and the data variation of that signal. Robust and reproducible assays have a
Z′ factor ranging from 0.5 to 1. Consistent with a high-quality assay, the Z′ factor was 0.73
(Figure 2).
As further validation, the PMB assay was used to screen 2180 compounds combined from
the NCI Challenge, Diversity and Natural Product library sets and the results were compared
to those obtained using the previously validated fluorogenic ATPase assay.18 For this
comparative analysis, we considered different cut-off values for identifying primary hits and
selected 50% inhibition as the cut-off for both assays. This criterion provided maximum
overlap among the bona fide hits from the two assays. Using this cut-off, the PMB ATPase
assay resulted in a 0.32% hit rate, yielding seven primary hits above 50% inhibition (Figure
3), four of which were confirmed as bona fide hits in an IC50 study. Of the four confirmed
hits, three were found in common between both the fluorogenic ATPase assay and the PMB
ATPase assay. Remarkably, the three hits common to both assays shared a common
chemotype (Figure 3). The ability of the PMB ATPase assay to mine the same hits from the
NCI library as the fluorogenic ATPase assay18 confirmed that the former provides a reliable
method for identifying inhibitors of RecA in multi-thousand compound libraries.
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Although the NCI compounds used to validate the PMB ATPase assay inhibited RecA ATP
hydrolysis in vitro with IC50 values between 4 to 6 μM, they failed to demonstrate an
appreciable effect on the biological activities of RecA in liquid cultures of E. coli (data not
shown). Nevertheless, the ability to efficiently identify these compounds indicated that the
PMB ATPase assay was suitable for use with large chemical libraries. Therefore, we elected
to screen a more diverse combinatorial library donated to the BRITE Center by Biogen Idec
and comprising over 350,000 compounds. Using identical compound and reagent
concentrations, we performed a screen of 33,600 representative compounds from this
library. This “diversity” subset was selected to span the overall range of chemical diversity
space represented in the larger collection (data not shown). The HTS assay of the
compounds yielded a range of inhibitor activities, with > 91% of the compounds
characterized by a relative inhibitory activity between −10% and 20% (Figure 4).
Overall, the HTS assay yielded an average Z′ factor of 0.83 and a Z factor of 0.67,
demonstrating robust and reproducible behavior from plate to plate (Figure 5). Three plates
had a Z factor below 0.4 and were rejected during data analysis. At a threshold of 50%
inhibition, 73 hits (0.22% hit rate) were identified (Figure 4). Interestingly, 71 of the 73
primary hits could be categorized into one of five chemotype clades based on their
molecular similarity. These hit groupings will be referred to as clades A to E, with 31, 4, 22,
9 and 5 compounds in clades A, B, C, D and E, respectively. The fact that multiple hits arise
from the same chemotype was apparent in the raw data (Figure 4), in which groups of hits
were observed on the same plate. This pattern likely results from the original grouping of
similar compounds in the donated collection.
We independently synthesized nine compounds from clades A to C, and performed an IC50
study using the PMB ATPase assay to verify them as hits. IC50 values could be accurately
measured for all compounds, with A1 – A4 yielding IC50 values of 8, 20, 22 and 24 μM, B1
– B4 yielding IC50 values of 21, 21, 71 and 104 μM, and C1 having an IC50 of 19 μM.
Extrapolating these observations to the rest of the 71 primary hits belonging to one of the
five chemotype clades, we conclude that the PMB ATPase effectively mined the 33,600
member library for structurally related hits, and the identification of false positives was
minimized. The most potent hit, A1 (IC50 = 8 μM), was subjected to rigorous analysis of its
activity against an in vitro RecA-mediated strand-exchange reaction and SOS induction in
live bacterial cell cultures as described below.
Inhibition of RecA-catalyzed DNA three strand-exchange by clade A compounds
At a cellular level, RecA catalyzes a strand exchange reaction that is used to repair extensive
DNA damage with homologous DNA. To determine if compound A1 could inhibit this
biologically important reaction, it was assessed for inhibition of the RecA-mediated strand
exchange reaction using an established in vitro assay that serves as a paradigm for the
physiologic recombinational functions of RecA.17 In the assay, RecA is supplied with ϕχ174
cssDNA, linear dsDNA and ATP. Active RecA catalyzes the rapid exchange of a DNA
strand, thereby converting the substrates into new linear ssDNA and nicked circular dsDNA
products that are characterized by differences in their migration rates during gel
electrophoresis. Because ATP hydrolysis by RecA is an absolute requirement for strand
exchange,13 we examined the ability of A1 to interfere with this reaction. When A1 was
present at 25 μM, the reaction did not proceed at all, indicated by the absence of both three
DNA-strand intermediates bound to RecA as well as the newly resolved DNA products
(Figure 6).
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Clade A compounds attenuate ciprofloxacin-induced SOS gene expression
After demonstrating that clade A compounds were potent inhibitors of RecA's in vitro
ATPase and recombinase activities, we examined their effect on RecA-dependent induction
of the SOS response in liquid cultures of E. coli. The Sandler group recently reported the
ability to measure SOS gene expression in E. coli K-12 having a sulA-gfp fusion reporter
gene inserted into the chromosomal DNA (strain SS996).15 The sulA promoter is LexA-
regulated, and is induced 100-fold during the SOS response.15 We used SS996 cells to
determine the differential SOS expression effected by A1 following treatment with
ciprofloxacin, a topoisomerase II specific DNA-damaging antibiotic known to stimulate de-
repression of the SOS regulon.23 The RecA-dependent expression of GFP (corresponding to
SOS induction) could be measured amongst a population of bacteria exposed to
ciprofloxacin and comparatively analyzed to bacterial cultures given a combination of
ciprofloxacin and A1.
Cultures of SS996 were given either no compound, A1 only, ciprofloxacin only or a
combination of A1 and ciprofloxacin and allowed to incubate for 90 min at 37 °C. The
bacteria were then fixed and stained with formaldehyde and DAPI, then examined using a
40X objective and filters selected for DAPI and GFP. The fluorescence intensity of the
DAPI and GFP channels was analyzed and a ratio of GFP/DAPI intensity was calculated to
determine the relative GFP expression per cell (Figure 7). There was a noticeable decrease
in SOS expression in the presence of A1. Untreated bacteria had a relative GFP expression
of 0.76, while those treated with ciprofloxacin saw this value increase to 0.87. In the
presence of ciprofloxacin and A1, the relative GFP expression was observed to drop to 0.58.
Accordingly, at a value of 0.53, the bacteria treated with only A1 exhibited the lowest
relative GFP expression. The apparent effect of A1 alone was unexpected. We tentatively
attribute the observation that SOS was induced to a modest degree in the absence of
ciprofloxacin to one or a combination of the following facts: (1) many replication forks are
inactivated in aerobically growing bacteria even in the absence of SOS-inducing conditions;
24 and (2) any one of a number of environmental stresses, including oxidative stress, osmotic
stress, acoustic cavitations, pH changes, and high pressure, can induce the SOS response.25
DISCUSSION
The development of drug-resistant bacteria is an unavoidable outcome of antibacterial
chemotherapy of infectious diseases. Reducing the rate and extent of development of
resistance could have profound influence on human health. Although the mechanisms that
facilitate the de novo development, clonal spread, and horizontal transfer of resistance
factors are not fully understood, the rapid rate at which antibiotic-resistant pathogens arise is
likely due to a combination of genetic mutation introduced by stress-induced non-replicative
polymerases and gene transfer from commensal organisms. Recently, RecA has emerged as
a crucial player in these phenomena as well as in the modulation of cell killing by
bactericidal antibiotics.
One of our labs has undertaken a systematic approach towards developing inhibitors of
RecA that could attenuate bacterial DNA repair and stress-induced SOS mutagenesis,
thereby diminishing the organism's inherent antibiotic tolerance and its ability to evolve
resistance. Transition metal complexes,26 nucleotide analogs,12,19,20 structured peptides,27
and polysulfated naphthyl compounds18 have previously been identified as inhibitors of the
in vitro activities of RecA. Unfortunately, these compounds were not cell-permeable, or
were determined to have a pleiotropic effect on live bacteria, and the discovery of more
drug-like small molecule inhibitors of RecA was desirable. Towards this end, a well-known
phosphomolybdate blue phosphate detection assay21,22 was adapted to screen a collection of
35,780 small molecules for inhibition of ATP hydrolysis by RecA, resulting in the discovery
Wigle et al. Page 8













of six classes of small molecules that inhibited RecA in the range of 10 to 30 μM. The most
potent class of inhibitors, clade A compounds, were examined more closely to determine
their effect on the biological activities of RecA that lead to antibiotic tolerance and
resistance.
The first such activity of RecA associated with antibiotic survival is its ability to catalyze a
DNA strand exchange reaction that is employed in the recombinational repair of extensive
chromosomal damage.11 We examined the inhibitory activity of A1 using an in vitro assay
that provides a paradigm for the in vivo recombinational activity of RecA.17 The presence of
A1 at 25 μM completely inhibited the RecA-catalyzed strand exchange reaction.
At a physiologic level, RecA-catalyzed strand exchange can lead to two outcomes
depending on the source of the homologous dsDNA: (1) the DNA may originate from a
sister chromatid present during replication, replacing the damaged DNA with an exact copy
or (2) the DNA may originate from a foreign source taken up through transformation,
transduction or conjugation, and introduce genetic variation. The former possibility restores
DNA homeostasis with wild-type genes and allows bacteria to tolerate higher doses of
antibiotics that precipitate DNA damage,11 while the latter possibility leads to horizontal
transfer of genes that may confer antibiotic resistance.28 Therefore, we are currently
investigating the ability of A1 to interfere with these processes that are fundamental to the
survival of bacteria in the face of antibacterial exposure.
The second activity of RecA implicated in the antibiotic survival response is its ability to
induce the SOS regulon by stimulating the autoproteolysis of the LexA repressor.10,23,29–31
In E. coli, the SOS response is characterized by the temporal activation of up to 40 genes
that gradually increase the severity of the response taken towards DNA damage.32 At first,
the early SOS gene products are involved in the repair of moderate DNA damage by
nucleotide excision (e.g., UvrABCD) and recombination (e.g., RecA),33 but damage that is
irreparable by these means or that persists for an extended period causes the late SOS genes
to be expressed. Late SOS gene products include the error-prone DNA polymerases, PolIV
and PolV, which promote global mutagenesis in an apparent last-ditch effort to resume
normal cellular function.33 The induction of the SOS response is quickly amplified by
severe DNA damage, as RecA is over-expressed in the intermediary stages of the pathway.
Hence, it is likely that the RecA-activated SOS response initially allows for higher tolerance
to antibacterials by up-regulating DNA repair pathways, but can ultimately lead to
antibacterial resistance by means of up-regulating genomic mutation and horizontal gene
transfer if its expression is sustained.
To assess whether inhibitor A1 could attenuate SOS stimulated by the bactericidal agent
ciprofloxacin, RecA-dependent SOS gene expression was quantified in live cultures of E.
coli K-12 cells having a sulA-gfp fusion.15 We found that A1 was capable of substantially
reducing the induction of SOS under conditions simulating natural environmental stress and
also under conditions of genomic stress stimulated by the DNA damaging antibiotic
ciprofloxacin.
In summary, we have used a high-throughput target-based screening approach to identify a
class of compounds, best represented by its highest-affinity member A1, that has the
following activities: inhibition of RecA's ssDNA-dependent ATPase activity in vitro,
inhibition of RecA's DNA strand exchange activity in vitro, and attenuation of
ciprofloxacin-induced SOS gene expression in live E. coli cells. Overall, these results
represent the first proof-of-concept that a small-molecule inhibitor targeting RecA can
attenuate the SOS response in living bacteria. Although, the experiments described herein
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have focused on the effect of ciprofloxacin on E. coli, there is compelling evidence
suggesting that this strategy may be generalized to other antibacterials and other organisms.
While the mechanism by which quinolone antibacterials such as ciprofloxacin result in
RecA-activating persistent ssDNA is implied by their cellular target, recent data from the
Collins laboratory demonstrated that, in E. coli, members of three major classes of
bactericidal agents result in the production of DNA-damaging hydroxyl radicals.9 The same
study also showed that E. coli with loss-of-function recA mutations are sensitized to cell
killing by all three classes of bactericidal agents. This suggests that a cell-permeable RecA
inhibitor may enhance the potency of a broad spectrum of antibacterial agents.
In a formal sense, RecA is not essential for bacterial growth on supplemented laboratory
media. Nevertheless, bacteria having loss-of-function mutations in the recA gene have yet to
isolated from clinical sources and in vitro studies indicate that such RecA-deficient bacteria
are sensitized to antibiotic treatment9 and develop resistance much more slowly or not at all
(Singleton et al., unpublished results). Indeed, RecA is nearly ubiquitous among bacteria and
has one of the slowest evolutionary rates.34 RecA's high degree of conservation suggests that
it likely plays roles in other species similar to those in E. coli.11 In the rare bacterial species
lacking a defined SOS response, RecA is heavily relied upon for DNA repair and other
biological processes that may promote survival and even pathogenesis in a human host.35,36
Taken together, these data suggest that RecA may provide an ideal candidate for target-
based drug discovery of inhibitors that potentiate cell killing by frontline bactericidal agents
and attenuate the development of resistance in a broad spectrum of bacterial pathogens.
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Evaluation of the dependence of the phosphomolybdate blue (PMB) ATPase assay signal on
free phosphate (open circles) and initial ATP (filled circles) concentrations under otherwise
optimized conditions. In the presence of RecA (0.5 μM) and poly(dT) (5 μM-nts), the PMB
assay reagent produced a linear colorimetric response (absorbance at 650 nm, A650) when
free phosphate (Pi; open circles) was added up to 1.25 mM. In separate experiments, the
RecA-DNA ATPase reaction was allowed to proceed with various starting ATP
concentrations (0.01 – 3.5 mM). After 35 min, the reactions were stopped by addition of the
PMB assay reagent and the A650 signal was measured. The A650 values were plotted as a
function of initial [ATP] (filled circles), and the results demonstrate that the assay signal is
linear with ATP concentration up to 0.8 mM but is substantially nonlinear between 0.8 and
3.2 mM ATP.
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Reproducibility of the phosphomolybdate blue (PMB) assay for RecA-DNA ATPase
activity under optimal conditions. The absorbance at 650 nm (A650) was measured after 35
min in each well of a 384-well plate in the presence (open circles) or absence (filled circles)
of 5 μM-nts poly(dT). The concentration of ATP was 0.75 mM in the experiments. Each
data point indicates the A650 signal for each well from three different experiments on three
different days; the error bars indicate the standard deviation of each mean value. The overall
means for the positive signal control (no inhibitor added; open circles) and negative
background control (no poly(dT) added; filled circles) were 1.153 ± 0.038 (CV = 3.3%) and
0.622 ± 0.010 (CV = 1.6%), respectively. The signal-to-background ratio was 1.8 and the
signal-to-noise ratio was 14. The overall Z' factor was 0.73.
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Results from the screen of three National Cancer Institute libraries. A scatter plot of the
relative inhibition (%) effected by 2180 compounds combined from three NCI libraries
against RecA using the phosphomolybdate blue ATPase assay. Reactions proceeded for 35
min at 37 °C and contained RecA (0.5 μM), poly(dT) (5 μM-nts), ATP (0.75 mM), and
assessed compounds (final concentration 17 μM). There were seven primary hits above a
threshold of 50% inhibition. The structures of three confirmed hits sharing a similar scaffold
from the National Cancer Institute screen are depicted at right. The IC50 values
characterizing the three hits ranged from 4 to 6 μM.
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A total of 33,600 compounds were selected from a donated Biogen Idec library to represent
the overall chemical diversity of the library and were screened using the phosphomolybdate
blue ATPase assay. Reactions proceeded for 35 min at 37 °C and contained RecA (0.5 μM),
poly(dT) (5 μM-nts), ATP (0.75 mM), and assessed compounds (final concentration 17 μM).
In the upper panel, the screening results are represented as a scatter plot of relative inhibition
(%) effected by each compound. There were 73 primary hits above a threshold of 50%
inhibition. In the lower panel, a frequency distribution of the assay results is depicted as a
histogram, where the number of compounds in each bin (± 5% width) is plotted on a
logarithmic scale.
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Statistical analyses of each 384-well plate to determine the quality of the HTS assay
performed on the Biogen Idec compounds. Z′ factor analysis was performed on each plate
and the average Z′ factor value was 0.83 (upper panel). Z factor analysis was performed on
each plate and the average Z factor value was 0.67 (lower panel). Three plates had a Z factor
below 0.4 and were rejected during data analysis.
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The RecA mediated three-strand exchange reaction is inhibited by A1. In the absence of
inhibitor, the formation of joint molecules intermediates (JM) and new nicked circular
dsDNA product (P) from circular dsDNA and homologous cssDNA substrates (S) is
observed. In the presence of A1 (25 μM) however, JM and P are not observed.
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Inhibition of SOS induction by A1. Cultures of E. coli K-12 (2 mL, OD600 = 0.3) containing
a RecA/LexA-controlled sulA-gfp fluorescent reporter gene were given no compound, A1
(100 μM) only, ciprofloxacin (100 ng/mL) only, or a combination of the two and incubated
for 90 min at 37 °C. Then, the bacteria were briefly stained with DAPI and immediately
examined under a high-content epifluorescence microscope in 384-well microplates using
filters selected for DAPI and GFP (left). The intensity of the GFP signal was normalized to
the DAPI signal for all bacteria in each image and a ratio of GFP/DAPI intensity was
calculated to yield the total GFP response (right). A1 inhibited both wild type and
ciprofloxacin-induced SOS expression to similar levels.
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